[Socioeconomic studies of hemostaseologic therapy and anticoagulation]

Since hemostaseologic therapies have a great impact on the budget of public health insurance companies, the therapy of hemophilia, prophylaxis of thrombosis and thrombolysis should be evaluated in a socioeconomic way. The substitution therapy in hemophilia is consuming a great deal of health care resources. The patients require an expensive, chronic therapy which enables them to be integrated in a normal social life. A lot of patients get a prophylaxis against thrombosis. Anticoagulants have to be valued with respect to their cost-effectiveness-relation. If thrombolysis is evaluated economically, one will have to consider carefully the high letality of thrombosis, the savings for the prevention of an operation and the high impact of this therapy on health care bills. The steady increase in health care costs emphasizes the necessity of health economics. Physicians should run socioeconomic evaluations to prove the use of different medicines and therapies and to represent the clinical point of view and the part of the patients.